Riskpilot← Back to searchSign inGet full accessNOVOZYMES BIOINDUSTRIAL A/S
A/SActiveCVR 24257908Krogshøjvej 36Activities of holding companies · NACE 6421Est. 1974— employees
Revenue 2024
DKK -51K
+25% vs 2023
EBITDA margin
100.0%
-25% vs 2023
Equity ratio
99.8%
Financial strength
Net profit 2024
DKK -42K
+99% vs 2023
| Revenue | DKK -51K | +25% |
| EBITDA | DKK -51K | -25% |
| Net profit | DKK -42K | +99% |
| Total assets | DKK 25M | +0% |
| Equity | DKK 24,9M | +0% |
| Employees | — | — |
Legal name
NOVOZYMES BIOINDUSTRIAL A/S
CVR number
24257908
Legal form
Aktieselskab
NACE code
6421 · Activities of holding companies
Founded
4. april 1974
Share capital
DKK 4.600.000
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem eller af en direktør.
Company purpose
Selskabets formål er drift af og investering i forskning, udvikling, produktion og handel med biologiske løsninger, herunder bioteknologiske produkter og processer samt at drive virksomhed, der efter bestyrelsens nærmere bestemmelse står i forbindelse hermed. Selskabet tilstræber at drive sin virksomhed på bæredygtig og ansvarlig vis, herunder i økonomisk, miljømæssig og social henseende.
Address
Krogshøjvej 36
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -32 | -32 | -37 | -41 | -51 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -32 | -32 | -37 | -41 | -51 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -32 | -32 | -37 | -41 | -51 |
| Net financials | 2.494 | 652 | -2.945 | -3.996 | -2 |
| Profit before tax | 2.463 | 620 | -2.982 | -4.036 | -53 |
| Tax | -8 | -18 | -11 | -9 | -12 |
| Net profit | 2.471 | 637 | -2.971 | -4.027 | -42 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 31.589 | 32.270 | 29.039 | 25.016 | 24.985 |
| Equity | 28.837 | 29.474 | 29.004 | 24.977 | 24.935 |
| Long-term debt | 2.721 | 0 | 0 | 0 | 0 |
| Short-term debt | 31 | 2.796 | 35 | 39 | 49 |
| Total debt | 2.752 | 2.796 | 35 | 39 | 49 |
EBITDA margin
-5111800.0%
This company
15.8%
Market median
-32353265% vs market
20202024
Equity ratio
99.8%
This company
38.2%
Market median
+161% vs market
20202024
Return on equity
-0.2%
This company
18.4%
Market median
-101% vs market
20202024
Net profit margin
-4170000.0%
This company
8.1%
Market median
-51481581% vs market
20202024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LK Management | Management | 2024 |
| Former (6) | ||
MØ Chief Executive Officer | Chief Executive Officer | 1974 – 1995 |
BD Chief Executive Officer | Chief Executive Officer | 2006 – 2016 |
PA Chief Executive Officer | Chief Executive Officer | 2000 – 2006 |
RC Chief Executive Officer | Chief Executive Officer | 2016 – 2024 |
R Audit | Audit | 1974 – 1990 |
KA Management | Management | 1974 – 2000 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2023 | |
| Chairman | 2010 | |
| Former (9) | ||
| Board of Directors | 1974 – 1997 | |
| Chairman | 2007 – 2010 | |
| Board of Directors | 2013 – 2021 | |
| Board of Directors | 1997 – 2000 | |
| Board of Directors | 2021 – 2023 | |
| Board of Directors | 2017 – 2021 | |
| Chairman | 2000 – 2007 | |
| Board of Directors | 1974 – 1997 | |
| Board of Directors | 2007 – 2013 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2000 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
NOVOZYMES BIOINDUSTRIAL A/S Board members of NOVOZYMES BIOINDUSTRIAL A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mads Øvlisen | Chief Executive Officer | 0 companies |
| Benny Dalgaard Loft | Chief Executive Officer | 0 companies |
| Per Artur Fredrik Månsson | Chief Executive Officer | 0 companies |
| Lisbet Kragelund | Management | 0 companies |
| Randi Camilla Kinch Jensen | Chief Executive Officer | 0 companies |
| Revisam | Audit | 0 companies |
| Kurt Anker Nielsen | Management | 0 companies |
| Rainer Chapour Lehmann | Board of Directors | 0 companies |
| Bent Hauerberg | Board of Directors | 0 companies |
| Kristian Merser | Chairman | 0 companies |
| Andrew Patrick Fordyce | Board of Directors | 0 companies |
| Ole Falvig Ramsby | Board of Directors | 0 companies |
| Lars Green | Board of Directors | 0 companies |
| Mikkel Viltoft | Chairman | 0 companies |
| Tina Sejersgård Fanø | Board of Directors | 0 companies |
| Steen Riisgaard | Chairman | 0 companies |
| Mads Ravn Sørensen | Board of Directors | 0 companies |
| Peder Holk Nielsen | Board of Directors | 0 companies |